Browsing by Author "Badziklou, Kossi"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Comparison of Two Assays for Molecular Determination of Rifampin Resistance in Clinical Samples from Patients with Buruli Ulcer Disease
    (Journal of Clinical Microbiology, 2014-01-29) Phillips, Richard Odame; Jansson, Moritz; Beissner, Marcus; Badziklou, Kossi; Piten, Ebekalisai; et. al
    Buruli ulcer disease (BUD), caused by Mycobacterium ulcerans, involves the skin, subcutaneous fatty tissue, and bones and predominantly affects children 15 years of age. If left untreated, contractures may cause severe functional limitation. Standardized antimycobacterial treatment consists of rifampin (RMP) and streptomycin administered for 8 weeks. An oral regimen combiningRMPand clarithromycin is currently under clinical evaluation (1–3). Notwithstanding the efficiency of chemotherapy, treatment failures and various types of secondary lesions have been reported, suggesting the need for customized clinical management strategies (4–6).
  • Thumbnail Image
    Item
    Loop-Mediated Isothermal Amplification for Laboratory Confirmation of Buruli Ulcer Disease—Towards a Point-of-Care Test
    (PLOS Neglected Tropical Diseases, 2015-11-13) Beissner, Marcus; Phillips, Richard Odame; Battke, Florian; Bauer, Malkin; Badziklou, Kossi; et. al
    As the major burden of Buruli ulcer disease (BUD) occurs in remote rural areas, development of point-of-care (POC) tests is considered a research priority to bring diagnostic services closer to the patients. Loop-mediated isothermal amplification (LAMP), a simple, robust and cost-effective technology, has been selected as a promising POC test candidate. Three BUD-specific LAMP assays are available to date, but various technical challenges still hamper decentralized application. To overcome the requirement of cold-chains for transport and storage of reagents, the aim of this study was to establish a dry-reagentbased LAMP assay (DRB-LAMP) employing lyophilized reagents.